Fate Therapeutics (FATE) Net Margin (2012 - 2026)

Fate Therapeutics (FATE) has 14 years of Net Margin data on file, last reported at 11371.52% in Q1 2026.

• Quarterly Net Margin fell 106599.0% year-over-year to 11371.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4757.39% (up 261898.0% YoY) and the FY2025 annual result came in at 7894.25%, down 382201.0% from the prior year.
• Net Margin eased to 11371.52% in Q1 2026, from 2374.07% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 154.22% in Q1 2023 to a low of 22578.39% in Q4 2024.
• A 5-year average of 6942.4% and a median of 4324.7% in 2025 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2023 — Net Margin plunged 2112792 bps — and 2025, when it jumped 2020432 bps.
• Tracing FATE's Net Margin over 5 years: stood at 806.62% in 2022, then sank by 2619 bps to 21934.55% in 2023, then decreased by 3 bps to 22578.39% in 2024, then surged by 89 bps to 2374.07% in 2025, then tumbled by 379 bps to 11371.52% in 2026.
• The last three Net Margin figures came in at 11371.52% (Q1 2026), 2374.07% (Q4 2025), and 4324.7% (Q3 2025), per Business Quant data.